I
nterleukin-3 is a broadly acting regulatory protein of hemopoietic cell differentiation. It stimulates proliferation, survival, and differentiation of pluripotent hemopoietic stem cells, and promotes expansion of cells that differentiate into mature cell lineages. Interestingly, IL-3 also has the capacity to divert differentiation of already committed cells. In the presence of IL-3, cells of the osteoclast lineage differentiate into cells of the macrophage lineage (1) . IL-3 signals to cells via the IL-3R, which is composed of an IL-3-specific ␣-chain and a common ␤-chain shared with the GM-CSFR ␣-chain and the IL-5R ␣-chain (2, 3) .
Endothelial cells (EC) 3 express IL-3R ␣-and ␤-chains, and expression can be increased by stimulation with TNF-␣ and/or IFN-␥ (4) . EC respond to IL-3 by expressing IL-8 and E-selectin (5, 6) . Moreover, IL-3 promotes endothelial tube formation and directional migration (7) . Cultured EC have been identified as a source of IL-3 (8) . Whether EC-derived IL-3 has autocrine functions is unknown, as is the question of a role for IL-3 in EC differentiation.
EC invest two distinct vascular trees, one building the transport system for blood and the other for lymph. They differ by morphology and phenotype as reviewed recently by several authors (9 -13) . Established markers for human lymphatic cells are, for example, Prox-1 (14) , podoplanin (15, 16) (also called T1␣ (17) or gp36 (18) ), vascular endothelial growth factor (VEGF)R-3 (19, 20) , and lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) (21) . Also for blood EC (BEC), lineage-specific genes have been identified by transcriptional profiling (22) (23) (24) , among constitutively expressed markers are N-cadherin (22) (23) (24) , pathologische anatomie Leiden-endothelium Ag (PAL-E) (for microvessels) (16, 25) , or CXCR4 (22, 23) . During embryogenesis, factors governing lymphatic differentiation are well described. The transcription factor Prox-1 is the earliest detectable marker of lymphatic differentiation and is essential for differentiation of lymphatic EC (LEC) from the anterior cardinal vein endothelium (14, 26, 27) . Lymphangiogenesis is regulated by growth factors VEGF-C and VEGF-D and their receptor VEGFR-3 (20, 28 -30) . The transmembrane mucoprotein podoplanin was shown to be important for the correct lymphatic network formation (26) . In the adult organism, the situation is more complex and less defined. For example, in some tumors and in inflammation, the lymphatic growth factor receptor VEGFR-3 is expressed on proliferating lymphatic and blood vessels, resulting in VEGF-C-induced lymph and blood vessel formation (31) (32) (33) (34) . This raises the question whether additional factors exist, which determine differentiation of LEC within the adult organism. In this study, we demonstrate that IL-3 regulates expression of LEC-specific markers Prox-1 and podoplanin.
Materials and Methods

Cells
HUVEC were isolated as described (35) and cultured in IMDM with 20% FCS, glutamine (2 mM; Invitrogen Life Technologies, Carlsbad, CA), penicillin (100 U/ml), streptomycin (100 g/ml; both Invitrogen Life Technologies), and heparin/ECGS (PromoCell, Heidelberg, Germany).
Foreskin-derived microvascular EC were isolated and cultured as described (36) . Briefly, foreskins were treated with dispase (Invitrogen Life Technologies) for 20 min at 37°C, followed by mechanically scraping EC with a cell scraper. Cells were then seeded into fibronectin-coated wells and cultured in EC growth medium (MV/ECGS; PromoCell). At passage 1, BEC and LEC were separated by magnetic sorting with an anti-podoplanin serum (15, 16) .
Antibodies
First step Abs were as follows: anti-Prox-1 (RDI, Flanders, NJ), antimacrophage mannose receptor (BD Pharmingen, San Jose, CA), PAL-E (RDI), anti-N-cadherin (BD Pharmingen), FITC-labeled CD31 (Immunotech, Marseille, France), anti-IL-3R ␣-chain Ab for FACS (clone 9F5), and blocking anti-IL-3R ␣-chain Ab (clone 7G3; both BD Pharmingen). As a specificity control for the anti-podoplanin serum, we raised a mouse monoclonal anti-human podoplanin Ab using peptide GASTGQPEDDTETT GLEGG (aa [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] as the Ag; a rabbit anti-human podoplanin serum was a gift from Dr. D. Kerjaschki (Department of Pathology, Medical University of Vienna). Isotype controls were purchased from Sigma-Aldrich (St. Louis, MO). Second step Abs were as follows: tetramethylrhodamine isothiocyanate-labeled goat anti-rabbit F(ab) 2 (Jackson ImmunoResearch Laboratories, West Grove, PA). PE-labeled goat anti-rabbit F(ab) 2 (BD Pharmingen), Alexa 488-labeled anti-rabbit IgG (Molecular Probes, Leiden, The Netherlands), FITC-labeled anti-mouse-IgG (Sigma-Aldrich), and HRP-labeled anti-mouse or anti-rabbit IgG (Bio-Rad, Hercules, CA).
FACS and laser scan analysis
For FACS, cells were detached from culture dishes using trypsin/EDTA. For laser scan imaging, cells were directly fixed on culture dishes with acetone/methanol (1:1) at Ϫ20°C for 10 min. Samples were then incubated with indicated first-step Abs followed by the appropriate fluorescence-labeled second-step Abs. Isotype-matched control Abs were used in parallel. Bound fluorescence was analyzed by FACScan (BD Biosciences, Mountain View, CA) or laser scan microscope (LSM 520; Zeiss, Oberkochen, Germany).
RT-PCR
Cells were lysed in lysis buffer (10 mM NaOH-HEPES (pH 7.8), 1.5 mM MgCl, 10 mM KCl, 1 mM DTT, 0.1% Nonidet P-40, and 1 U of RNase inhibitor (Roche, Basel, Switzerland)), and mRNA was isolated by using oligo(dT) beads (Dynal, Oslo, Norway). RNA was reverse transcribed with Superscript Reverse Transcriptase (Invitrogen Life Technologies) and hexamer primers (Roche) for 90 min at 42°C. One microliter of cDNA was then used for PCR with primers for podoplanin (forward, 5Ј-GAA GGT GTC AGC TCT GCT CT-3Ј; reverse, 5Ј-ACG TTG GCA GGG CGT AA-3Ј; 35 cycles), Prox-1 (forward, 5Ј-AAG ACA GAG CCT CTC CTG AAT C-3Ј; reverse, 5Ј-TTG CAC TTC CCG AAT AAG GTG AT-3Ј; 30 cycles), Lyve-1 (forward, 5Ј-GTG CTT CAG CCT GGT GTT G-3Ј; reverse, 5Ј-GCT TGG ACT CTT GGA CTC TTC-3Ј; 30 cycles), flt-4 (forward, 5Ј-AGC TCT CAG AGC TCA GAA GAG-3Ј; reverse, 5Ј-TTC TCT CTC TCT GCT TCA GCT-3Ј; 30 cycles). Primers for GAPDH were purchased from BD Clontech (Palo Alto, CA). As control for genomic DNA contamination, PCR was performed without reverse transcription. PCR conditions were 94°C for 30 s, 56°C for 40 s, and 72°C for 45 s. IL-3 mRNA was analyzed by real-time PCR using primers from assay 4327037T (Applied Biosystems, Foster City, CA) according to the instructions of the manufacturer.
ELISA
Cell culture supernatants were collected, protease inhibitors added (PMSF, leupeptin, and aprotinin), and analyzed using an IL-3 ELISA kit from R&D Systems (Minneapolis, MN) according to the instructions of the manufacturer. OD 450 was measured.
Western blot
Western blotting was performed as described previously (37) . Briefly, following cell lysis with Tris lysis buffer (containing 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 2 mM CaCl 2 , 1 mM PMSF, 10 g/ml aprotinin, 15 g/ml leupeptin, 1% Nonidet P-40, and 1% Triton X-100), proteins were separated on SDS polyacrylamide gels and blotted on polyvinylidene difluoride membranes. Blots were then incubated with indicated first-step Abs, followed by incubation with appropriate HRP-labeled second-step Abs. Signals were visualized by chemiluminescence (Super ECL System; Amersham Biosciences, Buckinghamshire, U.K.) and documented on Hyperfilm MP (Amersham Biosciences).
Results
Skin-derived EC acquire a lymphatic phenotype during subculture
Normal human skin contains approximately equal numbers of podoplanin-positive lymphatic vessels and podoplanin-negative blood vessels (an example of an immunofluorescence staining of human skin is shown in Fig. 1A ). As a consequence, mechanically scraped EC consisted of LEC and BEC at a ratio of ϳ1:1 (ranging from 2:1 to 1:2). A FACS analysis using anti-podoplanin Abs of primary isolated cells (passage 0 cells) is shown in Fig. 1B . During subculture, the numbers of podoplanin-negative cells continuously decreased, and numbers of podoplanin-positive cells increased (Fig. 1B) . Passage 6 cells consisted of 100% podoplanin-positive cells. As a positive control, we used CD31 Abs, which reacted equally with LEC and BEC (Fig. 1B) .
IL-3 is constitutively expressed in LEC
The molecular characterization of sorted LEC and BEC is shown in Fig. 1C . LEC are characterized by the expression of podoplanin, Flt-4, LYVE-1, Prox-1, and mannose receptor, and BEC by PAL-E and N-cadherin expression. To determine factors inducing podoplanin expression of mixed (nonsorted) LEC/BEC in culture, we screened cell culture supernatants of sorted LEC and BEC for cytokines. We found IL-3 consistently present in LEC and absent in BEC supernatants (Fig. 2A) . HUVEC were analyzed for comparison and also found negative for IL-3 (see also Nilsen et al. (8) ). Primary cultures, which, due to the isolation procedure, consisted of a mixture of LEC and BEC (mixed LEC/BEC), had slightly higher IL-3 release than in sorted LEC (by Student's t test, the difference compared with LEC was NS). IL-3 expression could be induced following stimulation with TNF-␣/IFN-␥ in LEC and in BEC, but IL-3 levels were ϳ10 times higher in stimulated LEC than in stimulated BEC ( Fig. 2A) . To confirm results, IL-3 mRNA was analyzed by real-time PCR: IL-3 mRNA was detectable in unstimulated LEC after a mean of 37 cycles, and was absent in unstimulated BEC even after 45 cycles (GAPDH was detectable after 21 cycles). Fig. 2B gives an example of a representative semiquantitative RT-PCR for IL-3.
It was previously shown that HUVEC express IL-3R ␣-and ␤-chain, and that expression is induced by TNF-␣/IFN-␥ (4). In this study, we show that also LEC and BEC express IL-3R (slightly higher in LEC than in BEC), and that expression was enhanced by TNF-␣/IFN-␥. Fig. 2C shows results for the ␣-chain; expression of the ␤-chain followed the pattern of the ␣-chain (data not shown) (6, 38, 39) . As a negative control, dermal fibroblasts were analyzed in parallel (Fig. 2C) .
IL-3 up-regulates podoplanin and Prox-1 expression
Cell surface expression of podoplanin was analyzed by FACS. Following IL-3 stimulation, podoplanin expression was enhanced in LEC (3-fold). In BEC and HUVEC, IL-3 induced de novo expression of podoplanin, albeit to a weaker extent (2-fold above baseline; Fig. 3 ). As a negative control, IL-3 was heat inactivated, which did not up-regulate podoplanin expression (Fig. 3) . Also TNF-␣/IFN-␥ induced podoplanin expression in LEC, BEC, and HUVEC. The addition of 1 g/ml anti-IL-3R ␣-chain Ab (clone 7G3, blocks signal transduction of the IL-3R (40)) inhibits TNF-␣/IFN-␥-induced podoplanin expression (Fig. 3) , which indicates that a TNF-␣/IFN-␥-induced IL-3 release is responsible for the observed podoplanin up-regulation. Following prestimulation with TNF-␣/IFN-␥, subsequent IL-3 stimulation further enhanced podoplanin expression in LEC (4-fold). Also in BEC and HUVEC, TNF-␣/IFN-␥ prestimulation followed by IL-3 was additive; podoplanin expression was further induced (Fig. 3) . Dermal fibroblasts analyzed as a negative control neither expressed podoplanin at baseline nor following TNF-␣/IFN-␥ and IL-3 stimulation (Fig. 3) .
FACS data were confirmed by podoplanin Western blots using whole-cell lysates of LEC and BEC (Fig. 4A) . Prox-1 expression was analyzed by immunofluorescence. In unstimulated LEC, Prox-1 was found in the nucleus in 100% of cells. In contrast, in unstimulated BEC, Prox-1 was undetectable, but was inducible upon stimulation with IL-3 (Fig. 4B) . Podoplanin and Prox-1 mRNA expression was analyzed by semiquantitative RT-PCR and were readily detectable in LEC at baseline and induced following IL-3 stimulation (Fig. 4C) . In contrast, unstimulated BEC and HUVEC were negative for podoplanin and Prox-1 mRNA, but was inducible following IL-3 stimulation (Fig. 4C) . As a negative control, dermal fibroblasts were analyzed and found negative for podoplanin and Prox-1 mRNA (Fig. 4C) .
Anti-IL-3R ␣-chain Abs inhibit Prox-1 and podoplanin expression
To analyze the role of endogenous IL-3, sorted LEC were cultured in the presence of an anti-IL-3R ␣-chain Ab (1 g/ml) (40) . In the presence of this blocking Ab, podoplanin expression in LEC decreased (as analyzed by immunofluorescence LSM imaging; Fig.  5A ). After 24 h of treatment of LEC, islands of cells emerged, which had lost podoplanin expression, whereas other islands showed persisting podoplanin expression. Islands of podoplaninpositive cells became continuously smaller, and after 168 h, podoplanin expression was almost completely lost in all LEC (Fig.  5A ). In the presence of a control Ab, cells remained positive for podoplanin (Fig. 5A, first panel) . Results were confirmed by FACS analysis. Fig. 5B gives the cumulative result of three independent experiments. After 168 h of anti-IL-3R␣ Ab treatment, ϳ90% of cells were negative for podoplanin expression, whereas an isotypematched control Ab had no effect (Fig. 5B) . After 168 h, the anti-IL-3R␣ Ab was removed by repeated washing and replaced by fresh medium. As shown in Fig. 5C , cells remained negative for podoplanin even after withdrawal of the Ab. Results from immunofluorescence and FACS were confirmed by RT-PCR; podoplanin and Prox-1 mRNA were undetectable following 72-h treatment with anti-IL-3R␣ Ab (Fig. 5B, inset) .
Anti-IL-3R␣ Ab treatment also altered cell morphology of cultured LEC. A representative example of transmission light microscopy images of LEC (cultured with isotype Ab), BEC (cultured with isotype Ab), and LEC cultured with anti-IL-3R␣ Ab is shown in Fig. 5D . LEC appeared as flattened cells, whereas BEC had a more spindled morphology. In the presence of anti-IL-3R␣, a population of spindled cells emerged comparable to those seen in pure BEC cultures. These islands correspond to the podoplanin-negative cells shown in Fig. 5A .
Discussion
Prox-1 is the earliest lymphatic marker during embryonic development (14, 26) and is thought to be the critical gene programming the lymphatic phenotype (14, 23, 27, 41) . Podoplanin expression occurs later and appears to be important for the lymphatic network formation (23, 26, 41) . Both molecules are constitutively expressed on lymphatic endothelium in the adult organism, but factors that induce or maintain their expression are currently unknown. In this study, we identified for the first time a soluble factor, IL-3, which is expressed in cultured LEC but not in BEC, and which is required to maintain expression of LEC-specific markers Prox-1 and podoplanin. Blocking IL-3 effects leads to a loss of expression of these molecules in cultured LEC.
It should be noted that, during embryogenesis, IL-3 does not appear to be the critical factor for the formation of the lymphatic tree, because IL-3-deficient animals have no severe lymphatic dysfunction. However, current reports have not specifically searched for subtle changes in lymphatic function (42, 43) ; thus, the role of IL-3 during development has to remain open.
Another issue concerns the question of why the expression of IL- 3 has not yet been identified as a LEC-specific gene in previous gene expression arrays (22) (23) (24) . On the one hand, this might be due to the reported instability of IL-3 mRNA, which complicates detection of IL-3 mRNA (44, 45) . In contrast, this seeming discrepancy might be due to the very low IL-3 mRNA levels in unstimulated LEC cultures, which may have escaped detection in arrays. However, constitutive IL-3 expression levels are generally low in most cell types previously analyzed (46) , and even such low concentrations are biologically active in settings of an autocrine IL-3 release. IL-3 supplemented to the medium requires much higher concentrations to achieve biological activity (46) .
In our assays, committed cells were used, which were isolated and sorted from human foreskins and thus already differentiated into either a BEC or a LEC phenotype. Even in such differentiated cells, IL-3 was able to induce Prox-1 and podoplanin expression. Although IL-3-induced expression levels of Prox-1 and podoplanin were much lower in BEC than in LEC, it involved the whole cell population, excluding growth selection as the basis of this phenomenon. Moreover, phenotypic changes appeared within 12-24 h, and population doubling times in EC are 36 -48 h, which also argues against a growth selection phenomenon. We also show that first-line inflammatory cytokines TNF-␣/IFN-␥ induce podoplanin expression, and this also depended on IL-3 (because it is inhibited by anti-IL-3R␣ Abs). Moreover, TNF-␣/IFN-␥ prestimulation was additive to subsequent IL-3-induced Prox-1 and podoplanin expression. This additive effect is most likely based on TNF-␣/IFN-␥-induced IL-3R expression. Such a mechanism has been previously described for IL-3-induced MHC class II expression in HUVEC, where TNF-␣/IFN-␥ prestimulation increased IL-3R expression and subsequently MHC class II expression induced by IL-3 (4).
To date, IL-3 is the first soluble factor identified that is able to induce Prox-1 and podoplanin expression in differentiated EC. This IL-3 effect was seen in LEC and in BEC, which raises the intriguing question whether IL-3-treated BEC transdifferentiate into LEC. Based on current knowledge, the answer is complex, because (first) cultured LEC have a certain heterogeneous expression of lymphatic markers (e.g., LYVE-1 or VEGFR-3 may be absent). This phenomenon was reviewed by Saharinen et al. (47) and interpreted as the appearance of different LEC subpopulations. Second, the situation is more complicated in experiments where a FIGURE 4. A, Western blotting for IL-3-induced podoplanin expression. IL-3 (25 ng/ml) was added to the medium for 24 h. Cells were then lysed, and immunoblots were performed with the polyclonal rabbit anti-podoplanin serum, which detects two different gylcosylation forms, 28 and 38 kDa, respectively. As a loading control, immunoblots for CD31 expression are shown. B, Immunofluorescence laser scan images for Prox-1 expression. Prox-1 is seen in a nuclear localization (red) in untreated LEC, and immunofluorescence is enhanced following IL-3 stimulation. In contrast, Prox-1 is absent in unstimulated BEC and induced following IL-3 stimulation. To visualize cell margins, cells were double-stained with CD31 Abs in green. C, Semiquantitative RT-PCR for podoplanin and Prox-1 expression in unstimulated cells or following IL-3-stimulation for indicated times is shown. Fibroblasts were used as a negative control.
phenotypic switch from BEC into LEC was induced by, for example, overexpressing Prox-1 (23, 41) or by infection with Karposi sarcoma-associated herpes virus (HHV8) (48, 49) . Prox-1 overexpression in BEC induced only ϳ20% of lymphatic genes and repressed only ϳ40% of blood vessel genes. This is also true for HHV8 infection of blood vessel endothelium, where some, but not all, lymphatic markers were up-regulated, and some bloodspecific markers disappeared. Surprisingly, even Prox-1 was not induced in all experiments (48, 49) . Thus the definition of a true LEC or BEC phenotype still floats with accumulating data on these cells (reviewed by Saharinen et al. (47) ). In other words, we think that the question whether IL-3 induces a true BEC-to-LEC conversion or a hybrid form cannot be answered at present.
With regard to in vivo effects of IL-3, others have shown new vessel formation in mice injected with IL-3-containing Matrigel plugs, but at the time of this report, phenotypic markers for LEC 168 h; second panel) . Thereafter, the Ab was washed out, and cells were cultured in medium alone for another 48 and 168 h, respectively. Podoplanin expression remained negative even after withdrawal of the Ab (third and fourth panels). D, Anti-IL-3R␣ Ab treatment changes cell morphology. Transmission microscopic images of LEC (first image) and BEC (third image) treated with a control Ab. The image in the middle shows LEC treated with 1 g/ml anti-IL-3R␣ Ab for 48 h. The asterisk denotes flattened cells resembling LEC, and the circles denote more spindled cells resembling BEC.
were yet not well characterized, and thus distinctions between LEC and BEC were not made (7, 50) . Moreover, this type of experiment would not differentiate between lymphangiogenesis from pre-existing lymph vessels and lymph vessel formation through transdifferentiation or a combination thereof. Anyway, the possibility for IL-3 to induce lymphangiogenesis raises the question whether increased IL-3 activity in tumors is associated with a high metastatic potential. This was shown for rat mammary adenocarcinoma cell clones, which were highly metastatic when they produced high levels of IL-3, but were poorly metastatic when they had no IL-3 activity (51) . As a natural source of IL-3, tumor-infiltrating lymphocytes have to be considered (50, 52) . Finally, the effects of the proinflammatory cytokines TNF-␣ and IFN-␥ on Prox-1 and podoplanin expression raises the possibility that lymphangiogenesis observed in situations of chronic inflammation (53, 54) is in part mediated through transdifferentiation of BEC into LEC.
In conclusion, we show that endogenous IL-3 is required to maintain the LEC phenotype in culture, and the addition of IL-3 to BEC induces expression of LEC-specific markers. Our data support the possibility that BECs can reprogram their phenotype into LECs, and IL-3 may contribute to lymphangiogenesis in tumors or in settings of chronic inflammation.
